Eli Lilly and Company (LLY)

Market Cap	952.94B
Revenue (ttm)	59.42B
Net Income (ttm)	18.41B
Shares Out	895.38M
EPS (ttm)	20.44
PE Ratio	52.06
Forward PE	33.89
Dividend	$6.92 (0.65%)
Ex-Dividend Date	Feb 13, 2026

Volume	2,593,259
Open	1,083.73
Previous Close	1,087.38
Day's Range	1,063.02 - 1,084.32
52-Week Range	623.78 - 1,133.95
Beta	0.35
Analysts	Strong Buy
Price Target	1,104.00 (+3.73%)
Earnings Date	Feb 4, 2026

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: NYSE
• Ticker Symbol: LLY
• Website: https://www.lilly.com

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Analyst Summary

According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,104.0, which is an increase of 3.73% from the latest price.

Price Target

$1,104.0

(3.73% upside)

Analyst Consensus: Strong Buy